Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pralatrexate - Acrotech Biopharma

Drug Profile

Pralatrexate - Acrotech Biopharma

Alternative Names: 10-Propargyl-10-deazaaminopterin; Difolta; Folotyn; PDX

Latest Information Update: 18 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center; Southern Research Institute; SRI International
  • Developer Acrotech Biopharma; Columbia University; Mundipharma International; Rafa Laboratories; Servier
  • Class Antineoplastics; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma; Follicular lymphoma; Bladder cancer; Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase I/II Lymphoma; Multiple myeloma
  • No development reported B-cell lymphoma; Bladder cancer; Breast cancer; Cutaneous T-cell lymphoma; Hodgkin's disease; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 06 Mar 2019 Spectrum Pharmaceuticals completes sale of pralatrexate to Acrotech Biopharma
  • 28 Nov 2018 No recent reports of development identified for phase-I development in Peripheral-T-cell-lymphoma(Combination therapy, Newly diagnosed) in USA (IV, Injection)
  • 01 Nov 2018 Launched for Peripheral T-cell lymphoma (Second-line therapy or greater) in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top